Myeloproliferative neoplasms (MPN), including myelodysplastic syndromes (MDS) or acute myeloid leukaemia (AML) arising from MPN research hub

Assessing the safety and tolerability of oral ruxolitinib in combination with 5-azacitidine in patients with advanced phase myeloproliferative neoplasms (MPN), including myelodysplastic syndromes (MDS) or acute myeloid leukaemia (AML) arising from MPN.

This early-stage study is testing whether two medicines, ruxolitinib and azacitidine, can be safely used together. It is designed for people aged 16 and over who have an advanced blood disorder called a myeloproliferative neoplasm (MPN). Researchers want to see how well patients tolerate the combination and find the safest dose.